Monoclonal Antibody Treatment of Migraine

Facebooktwittergoogle_plusredditpinterestlinkedinmail

Our center is a site in a phase IIb trial of a compound named LBR-101. This is a monoclonal antibody directed against calcitonin gene-related peptide (CGRP). Phase I and II trials have been very promising. The medication is given by injection monthly. If CGRP is given by injection in migraineurs, all develop a migraine. If given to non-migraineurs, this does not occur. Further, CGRP in the blood is increased during an attack of migraine. Previous CGRP oral antagonists have all shown efficacy but also possible liver toxicity. Monoclonal antibodies do not have this risk. Inclusion criteria for the trial include at least 8 migraine days a month.

Dr. Florin is committed to treating all patients compassionately with state-of-the-art techniques while maintaining their dignity and independence. He views each patient encounter as a collaboration. Dr Florin has over 35 years of experience. He is Adjunct Clinical Professor at Keck School of Medicine (USC) and is the founder and medical director of the Fullerton Neurology and Headache Center. He has been recognized by the Orange County Medical Association as a Physician of Excellence in Neurology. US News and World Report ranks him in the top 10% of neurologists nationwide.

Posted in Headache Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

*

Menu Title